• About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
      • ADR Program
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact

Technology

OKYO’s Membrane Anchored Peptide (MAP) technology enabled the development of OK-101’s enhanced potential drug ‘residence’ time and potency at the ocular surface as well combating washout through inclusion of the lipid ‘anchor’ in the drug molecule.

Membrane Anchored Peptide (MAP) Platform

  • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
      • ADR Program
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact

© OKYO Pharma, Limited | 2023

Explore

  • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
      • ADR Program
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact

Follow

  • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
      • ADR Program
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact

Legal

  • Legal
  • Privacy Policy
MENU
  • About
    • Leadership
    • Scientific Advisory Board
    • Directors
  • Disease Focus
    • Dry Eye Disease
    • Non-infectious Anterior Uveitis
    • Allergic conjunctivitis
    • Ocular Pain
  • Technology
    • Chemerin Receptor
    • OK-101 Drug Candidate
    • Preclinical Data
  • Pipeline
    • Overview
    • OK-101 Development Timeline
  • Investors
    • Share Information
    • Shareholder Services
      • ADR Program
    • Investor Updates
    • SEC Filings
    • Corporate Governance
      • Corporate Documents
      • Corporate Information
      • Corporate Directory
  • News
    • Press Releases
    • Media
  • Contact